← Leaderboards
John A Zebala
Syntrix Biosystems, Inc.
$18,699,047
Attributed
$30,703,562
Total exposure
21
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.9M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$30,703,562 · 21
By mechanism
R44$22,795,220 · 11
R43$6,239,555 · 9
U44$1,668,787 · 1
Top collaborators
- Stuart J Kahn23 shared
- Joel R Morgan11 shared
- Aaron D Schuler5 shared
- Dean Yoshimasa Maeda3 shared
Most similar at Syntrix Biosystems, Inc.
Same institution · by research overlap
- Joel R Morgan$1,644,962
- Aaron D Schuler$1,538,086
Others in their field
Top investigators on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$266,816,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
Research focus
Pharmaceutical PreparationsSmall Business Innovation Research GrantDoseOralSafetyBaseResistanceExhibitsCostAdverse EffectsResearch Clinical TestingSuccessCyclic GmpAffectUnited StatesReportingClinical TrialsDrug KineticsMalignant NeoplasmsSitePre-ClinicalInhibitor/AntagonistRandomizedDisease Remission
Grant awards (62)
A Phase 2, Single-Arm Study of the CXCR1/2 Inhibitor SX-682 Plus Enzalutamide in Men with Abiraterone-Resistant Metastatic Castration Resistant Prostate Cancer (mCRPC)$903,852
R44 · FY2025 · CA
A Dose Expansion Study of SX-682 Alone and in Combination with Decitabine in MDS Patients$627,270
R44 · FY2025 · CA
A Phase 2, Single-Arm Study of the CXCR1/2 Inhibitor SX-682 Plus Enzalutamide in Men with Abiraterone-Resistant Metastatic Castration Resistant Prostate Cancer (mCRPC)$745,050
R44 · FY2024 · CA
A Dose Expansion Study of SX-682 Alone and in Combination with Decitabine in MDS Patients$400,000
R44 · FY2024 · CA
A Phase 2, Single-Arm Study of the CXCR1/2 Inhibitor SX-682 Plus Enzalutamide in Men with Abiraterone-Resistant Metastatic Castration Resistant Prostate Cancer (mCRPC)$400,000
R44 · FY2023 · CA
A Phase 1 Clinical Trial Evaluating the Novel Small Molecule Immuno-Oncology Antagonist SX-682 Alone and With Pembrolizumab in Metastatic Melanoma$651,354
R44 · FY2021 · CA
A Phase 1 Randomized Single Oral Dose Four Period Cross-Over Study Investigating Omnitram Dose Proportionality and Food Effect in Normal Human Subjects$80,191
R44 · FY2021 · DA
A Phase 1 Randomized Single Oral Dose Four Period Cross-Over Study Investigating Omnitram Dose Proportionality and Food Effect in Normal Human Subjects$1,204,753
R44 · FY2020 · DA
A Phase 1 Clinical Trial Evaluating the Novel Small Molecule Immuno-Oncology Antagonist SX-682 Alone and With Pembrolizumab in Metastatic Melanoma$223,334
R44 · FY2020 · CA
A Phase 1 Randomized Single Oral Dose Four Period Cross-Over Study Investigating Omnitram Dose Proportionality and Food Effect in Normal Human Subjects$204,489
R44 · FY2019 · DA
A Phase 1 Clinical Trial Evaluating the Novel Small Molecule Immuno-Oncology Antagonist SX-682 Alone and With Pembrolizumab in Metastatic Melanoma$1,125,311
R44 · FY2018 · CA
Overcoming Tramadol Resistance In CYP2D6 Poor Metabolizers: A Phase 1 Trial Demonstrating Analgesic Superiority of Omnitram to Tramadol in Subjects Coadministered Paroxetine$977,024
R44 · FY2018 · DA
Efficacy and resistance mechanisms of LD-aminopterin in psoriasis$304,057
U44 · FY2018 · AI
Overcoming Tramadol Resistance In CYP2D6 Poor Metabolizers: A Phase 1 Trial Demonstrating Analgesic Superiority of Omnitram to Tramadol in Subjects Coadministered Paroxetine$997,596
R44 · FY2017 · DA
Phase II clinical evaluation of Omnitram in neuropathic pain$657,180
R44 · FY2017 · DA
Efficacy and resistance mechanisms of LD-aminopterin in psoriasis$649,697
U44 · FY2017 · AI
A Phase 1 Clinical Trial Evaluating the Novel Small Molecule Immuno-Oncology Antagonist SX-682 Alone and With Pembrolizumab in Metastatic Melanoma$621,000
R44 · FY2017 · CA
Overcoming Tramadol Resistance In CYP2D6 Poor Metabolizers: A Phase 1 Trial Demonstrating Analgesic Superiority of Omnitram to Tramadol in Subjects Coadministered Paroxetine$990,418
R44 · FY2016 · DA
Phase II clinical evaluation of Omnitram in neuropathic pain$842,819
R44 · FY2016 · DA
Efficacy and resistance mechanisms of LD-aminopterin in psoriasis$490,033
U44 · FY2016 · AI
Phase II clinical evaluation of Omnitram in neuropathic pain$224,997
R44 · FY2015 · DA
Optimization of CXCR1/2 antagonist SX-576 for the treatment of BPD and COPD$1,887,898
R44 · FY2014 · HL
Overcoming Tramadol Resistance In CYP2D6 Poor Metabolizers$583,069
R44 · FY2014 · DA
Efficacy and resistance mechanisms of LD-aminopterin in psoriasis$225,000
U44 · FY2014 · AI
Overcoming Tramadol Resistance In CYP2D6 Poor Metabolizers$933,466
R44 · FY2013 · DA
Optimization of CXCR1/2 antagonist SX-576 for the treatment of BPD and COPD$1,147,002
R44 · FY2012 · HL
Overcoming Tramadol Resistance In CYP2D6 Poor Metabolizers$574,129
R44 · FY2012 · DA
Transition-State Analogue Inhibitors of Dihydrofolate Synthetase for MDR/XDR TB$280,745
R43 · FY2012 · AI · contact PI
Optimization of CXCR1/2 antagonist SX-576 for the treatment of BPD and COPD$811,424
R44 · FY2011 · HL
99mTc-DTB-Antifol-Pteroyls (RadioDAPs): Theranostics for Rheumatoid Arthritis$295,072
R43 · FY2011 · AR · contact PI
Transition-State Analogue Inhibitors of Dihydrofolate Synthetase for MDR/XDR TB$271,034
R43 · FY2011 · AI · contact PI
Overcoming Tramadol Resistance In CYP2D6 Poor Metabolizers$649,545
R43 · FY2010 · DA
PhotoMorph3 and PhotoPS3 - Novel Light-Activated Antisense Agents$348,876
R43 · FY2010 · GM
99mTc-DTB-Antifol-Pteroyls (RadioDAPs): Theranostics for Rheumatoid Arthritis$295,072
R43 · FY2010 · AR · contact PI
Aminotrexate A Novel Strategy to Replace Methotrexate in Psoriasis$202,936
R43 · FY2010 · AI · contact PI
Snap-To-It Probes$511,079
R44 · FY2009 · CA · contact PI
PhotoMorph3 and PhotoPS3 - Novel Light-Activated Antisense Agents$350,024
R43 · FY2009 · GM
Aminopterin for the Treatment of Severe Recalcitrant Atopic Dermatitis$293,574
R43 · FY2009 · AR
Aminotrexate A Novel Strategy to Replace Methotrexate in Psoriasis$257,247
R43 · FY2009 · AI · contact PI
Snap-To-It Probes$200,000
R44 · FY2009 · CA · contact PI
Snap-To-It Probes$137,268
R44 · FY2009 · CA · contact PI
Snap-To-It Probes$363,774
R44 · FY2008 · CA · contact PI
Aminopterin for the Treatment of Severe Recalcitrant Atopic Dermatitis$293,574
R43 · FY2008 · AR
Aminotrexate A Novel Strategy to Replace Methotrexate in Psoriasis$626,944
R43 · FY2007 · AI · contact PI
Snap-To-It Probes$236,980
R44 · FY2007 · CA · contact PI
Instrumentation For High-Resolution Analysis of Cancer$1
R44 · FY2007 · CA · contact PI
Artificial Antibody Mimetics$1
R44 · FY2007 · CA · contact PI
Aminotrexate A Novel Strategy to Replace Methotrexate in Psoriasis$791,030
R43 · FY2006 · AI · contact PI
Instrumentation For High-Resolution Analysis of Cancer$746,571
R44 · FY2005 · CA
Artificial Antibody Mimetics$725,229
R44 · FY2005 · CA
Instrumentation For High-Resolution Analysis of Cancer$750,754
R44 · FY2004 · CA
Artificial Antibody Mimetics$714,186
R44 · FY2004 · CA
Meta-Molding Arrays$250,000
R43 · FY2004 · DK
Meta-Molding Arrays$250,000
R43 · FY2003 · DK
Instrumentation For High-Resolution Analysis of Cancer$149,800
R44 · FY2003 · CA
Artificial Antibody Mimetics$149,800
R44 · FY2003 · CA
Light-Up PNA Arrays$140,951
R44 · FY2003 · CA
Snap-To-It PNA Arrays$87,086
R43 · FY2003 · CA
Novel GSTP Inhibitors As Potential Oral Myelostimulants$250,077
R43 · FY2002 · CA
Snap-To-It PNA Arrays$196,642
R43 · FY2002 · CA
Light-Up PNA Arrays$155,200
R44 · FY2002 · CA
Novel GSTP Inhibitors As Potential Oral Myelostimulants$250,077
R43 · FY2001 · CA